Daily Stock Setups

Cytori Finalizes Enrollment in International Breast Cancer Reconstruction Study

Posted on: Wed, 18 Nov 2009 23:16:00 EST

Symbols: CYTX

Do you know when to trade CYTX ?

Check for a PowerRating from TradingMarkets

Nov 19, 2009 (Close-Up Media via COMTEX) --
CYTX | Quote | Chart | News | PowerRating -- Cytori Therapeutics said that it has completed enrollment in a 70-patient, international breast cancer reconstruction study, Restore 2.

In a release, the Company noted:

The study is evaluating the use of cell-enriched fat grafting to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer. Interim data on the first 32 patients who have reached the six-month follow-up will be presented as a poster at the San Antonio Breast Cancer Symposium December 12, at 7 a.m. U.S. Central Time by Mrs. Eva Weiler-Mithoff, MD, lead investigator at the Glasgow Royal Infirmary.

The Cell-Enriched Breast Reconstruction procedure combines a patient's own naturally occurring adipose-derived regenerative cells (ADRCs) with their fat tissue. This cell-enriched fat graft is then injected into and around the defect area. In the Restore 2 study, the ADRCs were extracted from adipose tissue using Cytori's Celution800 System. Currently, there is no generally accepted reconstructive method for partial mastectomy patients as the majority of these women are not implant candidates, leaving patients with limited options.

The Restore 2 study is a prospective, multi-center, post-marketing study in which all patients were treated with their own ADRCs and fat tissue. The study is designed to assess patient and physician satisfaction, improvement in overall breast deformity, imaging, quality of life, and safety among other measures. 70 patients were treated at seven centers in the European Union. The highest enrolling sites were Hospital Gregorio Maranon, Glasgow Royal Infirmary, and KU-Leuven University Hospital.

"Completion of the Restore 2 study is important because it lays the foundation for optimal reimbursement in Europe for Cell-Enriched Breast Reconstruction using the Celution800 System," said Alex Milstein, MD, vice president of clinical development at Cytori. "Together with existing evidence on the Celution800 device, we believe the findings from Restore 2 will help physicians make the best possible treatment decisions for their patients. We would like to express our gratitude to all study participants, the investigators, and their teams for their dedication and support of Restore 2."

Cytori is committed to providing patients and physicians around the world with medical technologies, which harness the potential of adult regenerative cells from adipose tissue.

((Comments on this story may be sent to health@closeupmedia.com))

For full details on Cytori Therapeutics Inc (CYTX) CYTX. Cytori Therapeutics Inc (CYTX) has Short Term PowerRatings at TradingMarkets. Details on Cytori Therapeutics Inc (CYTX) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.